
Opinion|Videos|March 24, 2025
Adoption of Emerging Delivery Systems and Future Outlook for NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.
Advertisement
Video content above is prompted by the following:
- How easily can TAR-200 and other emerging delivery systems be adopted into clinical practice for the treatment of NMIBC?
- What are your thoughts on the future outlook for NMIBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
3
FDA approves cefepime and zidebactam for complicated UTI
4
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
5







